J Thorac Oncol 2024 Jan 24
Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
Related Questions
New answer by Medical Oncologist at University of Colorado (June 26, 2024)
CROWN [Solomon et al., PMID 38819031] - This was a practice-changing, 5-year update on the randomized phase 3 clinical trial of lorlatinib versus crizotinib in patients with...